Strides Pharma Science Limited develops and manufactures pharmaceutical products in Africa, Australia, North America, Europe, Asia, India, and internationally. The company operates through one segment: Pharmaceutical. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, CNS, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. In addition, the company offers market and trade in pharmaceutical and ancillary products. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.
Metrics to compare | SRID | Peers Peers - average of corresponding metrics from companies closely matching SRID: AJANTPHARM, ZYDUSLIFE, ALKEM, GLAND, APLLTD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSRIDPeersSector |
---|---|---|---|---|
P/E Ratio | 21.0x | 28.4x | −0.5x | |
PEG Ratio | 0.00 | 0.91 | 0.00 | |
Price/Book | 3.3x | 4.6x | 2.6x | |
Price / LTM Sales | 1.9x | 4.6x | 3.2x | |
Upside (Analyst Target) | 11.6% | 5.6% | 41.6% | |
Fair Value Upside | Unlock | 1.6% | 6.0% | Unlock |